News News Details

Recognized and Included in National-Level Yearbook! Efung Capital Listed as an Outstanding Private E

Date: 2025-07-30
Views: 0

The New Quality Productive Forces Seminar, co-hosted by the Macroeconomic Magazine of the National Development and Reform Commission and the Editorial Committee of the China Private Equity Fund Yearbook, was successfully held. During the seminar, the China Private Equity Fund Yearbook (2024) was officially released.

To provide a more comprehensive overview of the industry's development, the Editorial Committee of the China Private Equity Fund Yearbook conducted a comprehensive evaluation of over 20,000 private equity fund managers in China across more than 20 dimensions, leveraging its database and years of on-site due diligence. Taking into account the differences among securities, equity, and venture capital private equity fund managers, the Yearbook included the top 1% of the industry, representing more than 200 outstanding private equity fund managers. Among them, Efung Capital was recognized as an Outstanding Private Equity Manager (Venture Capital) in the China Private Equity Fund Yearbook (2024), thanks to its exceptional investment performance and deep industry insights.

Looking ahead, Efung Capital will continue to深耕 the biopharmaceutical and hard technology sectors, leveraging its professional investment team and extensive industry resources. Through capital empowerment and resource connection, Efung Capital will facilitate the transformation and commercialization of technological achievements, partnering with portfolio companies to navigate market cycles and jointly drive the high-quality development of China's healthcare and technological innovation sectors.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务